CLINICAL EVIDENCE — HEMODYNAMICS TRANSCATHETER AORTIC VALVE REPLACEMENT (TAVR)

Clinical Evidence Demonstrates Industry-Leading Hemodynamics

The Medtronic transcatheter aortic valve with a self-expanding, supra-annular design delivers industry-leading hemodynamics. See the recently released clinical evidence on our newest generation TAVR device as well as longer-term hemodynamic performance out to 5 years on this proven platform:

Evolut Pro 29mm


Newest Generation Evolut PRO Study1

The Evolut PRO Study is a prospective, multicenter, non-randomized single-arm study. Primary safety endpoints were all-cause mortality and disabling stroke at 30 days. Primary efficacy endpoint was percentage of patients with none or trace aortic regurgitation at 30 days.

  • Study Status/Duration: 1 year outcomes reported/5-year follow-up
  • Sample Size: N = 60
  • Device: Evolut PRO TAV

SURTAVI (Intermediate Risk) Trial2

The SURTAVI Clinical Trial is a prospective, multinational, randomized clinical trial evaluating the CoreValve and Evolut R systems versus surgery in patients with symptomatic severe aortic stenosis at intermediate surgical risk.

  • Study Status/Duration: 1-year full Kaplan-Meier and 2-year Bayesian outcomes reported/10-year follow-up
  • Sample Size: N = 864 TAVI, 796 SAVR
  • Devices: CoreValve 84% / Evolut R 16% TAVs

ADVANCE Post-Market Study3

The CoreValve ADVANCE Study is a multicenter, prospective, single-arm observational study to evaluate safety and performance of the CoreValve system in a routine hospital setting.

  • Study Status/Duration: 5-year outcomes reported/5-year follow-up
  • Sample Size: N = 1,015
  • Devices: CoreValve, TAV

CoreValve Advance 5-years

LIFELINE CARDIOVASCULAR TECHNICAL SUPPORT

877-526-7890

rs.cstechsupport@medtronic.com

STAY

INFORMED

Receive email updates about Medtronic TAVR.

SIGN UP

MEDTRONIC

ACADEMY

View more clinical data and access procedural resources.

LOG IN OR REGISTER

1

Williams, as presented at 2018 ACC

2

Reardon MJ, Van Mieghem NM, Popma JJ, et al. Surgical or Transcatheter Aortic-Valve Replacement in Intermediate-Risk Patients. N Engl J Med. April 6, 2017;376(14):1321-1331.

3

Gerckens U, Tamburino C, Bleiziffer S, et al. Final 5-year clinical and echocardiographic results for treatment of severe aortic stenosis with a self-expanding bioprosthesis from the ADVANCE Study. Eur Heart J. September 21, 2017;38(36):2729-2738.